JAC Advance Access published online on November 18, 2002
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkf248
© 2002 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Paper
1 Antimicrobial Research Centre and Division of Microbiology,
University of Leeds, Leeds LS2 9JT, UK
* Corresponding author. E-mail: i.chopra{at}leeds.ac.uk.
Received 21 June 2002
; revised 10 September 2002
; accepted 15 September 2002
The antimicrobial properties of cephalosporin P1, an
antibiotic structurally related to fusidic acid, were examined.
Cephalosporin P1 exhibited potent activity against methicillin-sensitive Staphylococcus aureus, methicillin-resistant S. aureus and vancomycin-intermediate S.
aureus. Mutants of S. aureus resistant to
cephalosporin P1 arose with a frequency of 1.6 x 10-6 for selections
at 4 x MIC, a frequency similar to that
for fusidic acid. The mutations conferred cross-resistance to fusidic
acid and mapped in fusA, the gene encoding elongation
factor G. Cross-resistance between cephalosporin P1 and fusidic
acid also occurred for S. aureus fusA mutants selected
with fusidic acid, and in fusidic acid-resistant clinical isolates.
Plasmid pUB101, which mediates resistance to fusidic acid in S.
aureus, also conferred resistance to cephalosporin P1. Escherichia
coli was intrinsically resistant to both fusidic acid and cephalosporin
P1, but deletion of the AcrAB efflux pump resulted in susceptibility
to both antibiotics. Although complete cross-resistance between
fusidic acid and cephalosporin P1 was demonstrated, the nature
and location of fusA mutations in S.
aureus when cephalosporin P1 was the selective agent frequently
differed from those selected with fusidic acid. This may reflect
differences in the interaction of the two antibiotics with the translational
apparatus, which results in the selection of separate mutation classes
for each antibiotic. Furthermore, in three of 14 mutants selected
with fusidic acid, resistance was attributed to mutations lying
outside fusA. In contrast, mutations in 10 mutants
selected with cephalosporin P1 were all located in fusA.
Keywords: cephalosporin P1, fusidic acid, Staphylococcus
aureus, resistance
Antimicrobial activity and mechanisms of resistance
to
cephalosporin P1, an antibiotic related to fusidic acid
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Al-Hamad, M. Upton, and J. Burnie Molecular cloning and characterization of SmrA, a novel ABC multidrug efflux pump from Stenotrophomonas maltophilia J. Antimicrob. Chemother., October 1, 2009; 64(4): 731 - 734. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Rosner and R. G. Martin An Excretory Function for the Escherichia coli Outer Membrane Pore TolC: Upregulation of marA and soxS Transcription and Rob Activity Due to Metabolites Accumulated in tolC Mutants J. Bacteriol., August 15, 2009; 191(16): 5283 - 5292. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Noren, T. Akerlund, M. Wullt, L. G. Burman, and M. Unemo Mutations in fusA Associated with Posttherapy Fusidic Acid Resistance in Clostridium difficile Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1840 - 1843. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Stubbings, J. Bostock, E. Ingham, and I. Chopra Deletion of the Multiple-Drug Efflux Pump AcrAB in Escherichia coli Prolongs the Postantibiotic Effect Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1206 - 1208. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. O'Neill, A. R. Larsen, A. S. Henriksen, and I. Chopra A Fusidic Acid-Resistant Epidemic Strain of Staphylococcus aureus Carries the fusB Determinant, whereas fusA Mutations Are Prevalent in Other Resistant Isolates Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3594 - 3597. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Stubbings, J. M. Bostock, E. Ingham, and I. Chopra Assessment of a microplate method for determining the post-antibiotic effect in Staphylococcus aureus and Escherichia coli J. Antimicrob. Chemother., July 1, 2004; 54(1): 139 - 143. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Miller, A. J. O'Neill, and I. Chopra Escherichia coli Mutators Present an Enhanced Risk for Emergence of Antibiotic Resistance during Urinary Tract Infections Antimicrob. Agents Chemother., January 1, 2004; 48(1): 23 - 29. [Abstract] [Full Text] [PDF] |
||||


